ODI Pharma AB (ODI.ST)

SEK 2.68

(21.82%)

EBITDA Summary of ODI Pharma AB

  • ODI Pharma AB's latest annual EBITDA in 2023 was 1.36 Million SEK , up 80.34% from previous year.
  • ODI Pharma AB's latest quarterly EBITDA in 2023 FY was N/A , up 80.34% from previous quarter.
  • ODI Pharma AB reported an annual EBITDA of -6.89 Million SEK in 2022, up 5.76% from previous year.
  • ODI Pharma AB reported an annual EBITDA of -7.2 Million SEK in 2021, down -84.38% from previous year.
  • ODI Pharma AB reported a quarterly EBITDA of 1.45 Million SEK for 2023 Q3, up 178.49% from previous quarter.
  • ODI Pharma AB reported a quarterly EBITDA of -1.17 Million SEK for 2023 Q1, up 55.23% from previous quarter.

Annual EBITDA Chart of ODI Pharma AB (2023 - 2018)

Historical Annual EBITDA of ODI Pharma AB (2023 - 2018)

Year EBITDA EBITDA Growth
2023 1.36 Million SEK 80.34%
2022 -6.89 Million SEK 5.76%
2021 -7.2 Million SEK -84.38%
2020 -3.96 Million SEK 16.71%
2019 -4.92 Million SEK -36.03%
2018 -3.33 Million SEK 0.0%

Peer EBITDA Comparison of ODI Pharma AB

Name EBITDA EBITDA Difference
AcuCort AB -13.69 Million SEK 109.987%
AlzeCure Pharma AB (publ) -37.86 Million SEK 103.611%
BioGaia AB (publ) 466.19 Million SEK 99.707%
Enzymatica AB (publ) -41.12 Million SEK 103.325%
Enorama Pharma AB (publ) -43.05 Million SEK 103.176%
Gabather AB (publ) 37 Thousand SEK -3595.576%
Klaria Pharma Holding AB (publ.) -14.77 Million SEK 109.258%
Moberg Pharma AB (publ) -26.95 Million SEK 105.072%
Nanexa AB (publ) -70.79 Million SEK 101.932%
Newbury Pharmaceuticals AB (publ) -12.34 Million SEK 111.081%
Orexo AB (publ) -22 Million SEK 106.215%
Probi AB (publ) 115.61 Million SEK 98.817%
Swedencare AB (publ) 484 Million SEK 99.717%
Swedish Orphan Biovitrum AB (publ) 7.23 Billion SEK 99.981%
Toleranzia AB -7.39 Million SEK 118.483%
Vivesto AB -89.75 Million SEK 101.523%